Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.66 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.59 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.59 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.59 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357869 | 0.99 | KMO (0.67) | KMOALOX15MAPTPKMMRGPRX4 | |
| SCHEMBL5743752 | 0.86 | ALDH1A1 (0.66) | KMOALOX15MAPTPKMMRGPRX4 | |
| SCHEMBL4203044 | 0.85 | ALDH1A1 (0.64) | ALOX15MAPTPKMMRGPRX4LMNA | |
| SCHEMBL8698430 | 0.85 | KMO (0.63) | KMOALOX15MAPTPKMMRGPRX4 | |
| SCHEMBL475555 | 0.84 | MRGPRX4 (0.54) | KMOALOX15MAPTPKMMRGPRX4 | |
| SCHEMBL1490676 | 0.84 | PLOD2 (0.60) | PLOD2PLOD3PLOD1LMNAALDH1A1 | |
| SCHEMBL28692105 | 0.83 | PLOD2 (0.67) | KMOALOX15MAPTPKMMRGPRX4 | |
| SCHEMBL30474594 | 0.83 | PLOD2 (0.67) | KMOALOX15MAPTPKMMRGPRX4 | |
| SCHEMBL13724478 | 0.83 | KMO (0.74) | KMOMAPTPLOD2PLOD3PLOD1 | |
| SCHEMBL1645102 | 0.83 | MRGPRX4 (0.60) | ALOX15MAPTPKMMRGPRX4PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928162-B | Synthesis method of substituted N-phenyl morpholine compound | 韶远科技（上海)有限公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021143924-A1 | BORIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-2744330-B1 | SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE) BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIITORS | UNIV UTAH RES FOUND (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3010915-B1 | SUBSTITUTED (3-(5-CHLORO-2-HYDROXYPHENYL)-1-BENZOYL-1H-PYRAZOLE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | UNIV UTAH RES FOUND (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9642857-B2 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9555024-B2 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-6888029-B2 | Transition-metal-catalyzed carbon-nitrogen bond-forming methods using carbene ligands | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20040044250-A1 | Transition-metal-catalyzed carbon-nitrogen bond-forming methods using carbene ligands | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-04 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1354887-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Insitute of Technology (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | KMO 627/4885ALOX15 1115/4885MAPT 4858/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | KMO 1576/4885ALOX15 1526/4885MAPT 4807/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | KMO 883/4885ALOX15 1278/4885MAPT 4777/4885 |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO2, SUMO1 | KMO 1623/4885ALOX15 2354/4885MAPT 1726/4885 |
| US-20040044250-A1 | Transition-metal-catalyzed carbon-nitrogen bond-forming methods using carbene ligands | PAM, DAO, NAA15 | KMO 23/4885ALOX15 644/4885MAPT 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.